Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to “Sell” Rating by StockNews.com
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday. Oramed Pharmaceuticals Trading Down 2.3% Oramed Pharmaceuticals stock opened at $2.15 on Friday. The firm has a market capitalization of $87.83 million, a price-to-earnings ratio of 19.55 […]
